



**AVID RADIOPHARMACEUTICALS TO PRESENT AT 21ST ANNUAL
PIPER JAFFRAY HEALTH CARE CONFERENCE
ON WEDNESDAY, DECEMBER 2ND**

Philadelphia, PA, November 25, 2009 – [Avid Radiopharmaceuticals, Inc.](#), a leader in the development of products with the potential for earlier and more effective detection, diagnosis and monitoring of brain disorders, today announced that [Daniel M. Skovronsky](#), M.D., Ph.D., Founder and CEO, will present at the [21st Annual Piper Jaffray Health Care Conference](#). The conference will be held December 1-2, 2009 at the New York Palace Hotel in New York City.

Dr. Skovronsky's presentation is scheduled for Wednesday, December 2, 2009 at 9:50 a.m. EST. He will present an update on Phase III clinical trials and commercialization efforts for the company's amyloid imaging compound ¹⁸F-AV-45 (AV-45), the most advanced F-18 compound in development for imaging amyloid plaque in the brain associated with Alzheimer's disease. Avid's AV-45 was the first amyloid imaging compound to enter multi-center, IND-approved, clinical studies in the U.S., and has now been studied in more than 600 individuals, ranging from cognitively normal individuals to those with Alzheimer's disease. AV-45 entered a pivotal registration study earlier this year using a unique trial design that was based upon recommendations by the FDA peripheral and CNS advisory committee in October 2008.

Avid's second program, ¹⁸F-AV-133 (AV-133) PET imaging of the vesicular monoamine transporter 2 (VMAT2) in patients with suspected dopaminergic degeneration, is currently in Phase II clinical trials. AV-133 has also been shown to be a marker for beta cells of the pancreas in preclinical studies. The compound is now in Phase I studies to test the ability of this molecular imaging agent to distinguish type 1 and type 2 diabetes subjects from healthy normal individuals based on a PET scan of the pancreas.

About Avid Radiopharmaceuticals, Inc.

Avid Radiopharmaceuticals is a leader in the development of molecular imaging products with the potential for earlier and more effective detection, diagnosis and monitoring of major chronic human diseases. Based in Philadelphia, PA, the company is a pioneer in the development of molecular imaging agents for Alzheimer's disease that could lead to earlier diagnosis and better evaluation of drugs designed to prevent or reverse amyloid plaque build-up in the brain. Avid is currently conducting Phase III clinical studies of ¹⁸F-AV-45 for imaging amyloid plaques in Alzheimer's disease, and is in Phase I and II trials with ¹⁸F-AV-133 for imaging the vesicular monoamine transporter (VMAT2) in diseases involving dopaminergic degeneration (Parkinson's disease and Dementia with Lewy Bodies) and beta cell dysfunction (Type I and Type II Diabetes Mellitus). For more information, please visit www.avidrp.com.



CONTACT:

Richard A. Baron
Chief Financial Officer
baron@avidrp.com
215-298-0723

###